ClinicalTrials.gg
RecruitingNCT07341074BRAIN-RESETUpdated Jun 26, 2026

Multicenter Early Intervention Study in Adults With Complaints After Mild Traumatic Brain Injury

An interventional study of Treatment by physical- and/or occupational therapist and Psychoeducation via telephonic counselling in Mild Traumatic Brain Injury, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
655
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Rationale: In the Netherlands, traumatic brain injury (TBI) is one of the most frequent neurological diseases and one of the leading causes of disability. Presumably, about half of the total Dutch population will get a TBI during their lifetime. The majority, about 85%, of patients suffers from a mild TBI (mTBI). The incidence of mTBI is estimated at 68,000 patients each year, but this is an underestimation as patients seen at the general practitioner's offices are not taken into account. In general, the prognosis of mTBI is relatively good, however more than 70% of patient still have one or more post-traumatic complaints at six months post-injury influencing resumption of daily (social) activities and return to work/study. Considering the high annual incidence of mTBI the number of patients with incomplete recovery has high social impact accompanied with excessive health care related costs. Post-traumatic complaints in the chronic phase postinjury are considered therapy resistant and so far no evidence based treatment is available. Hence, the most appropriate strategy is to prevent complaints present in the (sub)acute phase after injury to become persistent to improve functional outcome and quality of life.

Objective: The main aim of this study is to improve early care for patients suffering from post-traumatic complaints after mTBI through the development of effective symptom-guided tailored interventions. Nowadays, no effective therapy is available and care-as-usual consists of a wait-and-see policy. Early therapy will reduce posttraumatic complaints and facilitate earlier return to daily activities and work or study, consequently quality of life will be improved as well. This in turn will result in less healthcare consumption and lower societal costs.

Study design: The investigators propose a prospective three-arm multicenter open randomized controlled trial (RCT), randomizing participants between two interventions and care as usual. The end-point assessment is blinded.

Study population: Adults, aged 18-70 years, diagnosed with a mTBI at the Emergency Department (ED) of the participating hospitals within 24 hours after injury are eligible for inclusion.

Intervention: At two weeks post-injury the presence, severity, and type of post-traumatic complaints are assessed using the Rivermead Postconcussive complaints Questionnaire (RPQ). If a predefined minimum of complaints is present, a participant is randomised for one of the two interventions or the control group. The first intervention arm consists of symptom-targeted treatment with assignment to physical and/or occupational therapy. The second intervention arm involves psychoeducation about the complaints through telephonic counselling. The interventions are offered during three weeks from week 3-6 week post-injury.

Main study parameters/endpoints: The primary outcome measure is the total RPQ sum score at three months postinjury. The secondary outcome measures are functional outcome and quality of life.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants included in treatment arm 1 will undergo three to six therapy sessions with a physiotherapist and/or occupational therapist over a period of three weeks. This regimen may be potentially burdensome by its frequency but the risks associated with these treatments are low. Participants randomised to treatment arm 2 will receive three telephone calls over the course of three weeks, during which psychoeducation will be provided. This intervention is minimally burdensome and risk-free. All participants included in the interventional part of the study will complete questionnaires at three time points after injury and will receive two follow-up telephone calls three and six months post-injury for outcome assessment. This process is minimally burdensome and poses no risk. Finally, participants included in the registry will complete a limited set of questionnaires at three time points, which is also minimally burdensome and riskfree.

02

Conditions studied

  • Mild Traumatic Brain Injury

Browse trials for

03

In context

Brain Concussion

637 studies on the registry are indexed under Brain Concussion; 163 are open to participants now.

This study's planned enrollment of 655 is above the median of 63 across 446 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years
  • Seen at the ED within 24 hours after trauma
  • Loss of consciousness (\<30min.)
  • Post-traumatic amnesia (\<24hrs)
  • Glasgow Coma Scale (GCS) score of 13-15 after initial resuscitation at the ED
  • Comprehension of Dutch language

Exclusion criteria

Exclusion Criteria:

  • Inability for follow-up
  • Chronic substance abuse (alcohol and/or drugs)
  • Severe psychiatric disease
  • Documented previous traumatic brain injury for which the patient was admitted
  • Dementia and/or other severe comorbidities
  • Current treatment by physical and/or occupational therapist for other indications
  • Language barriers or illiteracy prohibiting understanding and completion of questionnaires
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
655 participants (estimated)

Study arms

  • Experimental
    Treatment by physical- and or occupational therapist

    Other: Treatment by physical- and/or occupational therapist

  • Experimental
    Psychoeducation via telephonic counseling

    Behavioral: Psychoeducation via telephonic counselling

  • No intervention
    Care as usual

Interventions

  • OtherTreatment by physical- and/or occupational therapist

    Patients that are randomized in intervention arm 1 (physical- or occupational therapy) will be allocated for treatment by a physical therapist if the complaints are in the somatic domain, by an occupational therapist if the complaints are in the cognitive domain, and by both if the complaints are in both domains.

  • BehavioralPsychoeducation via telephonic counselling

    Patients randomised to the psychoeducation arm will be contacted by a research nurse by telephone three times between weeks 3 and 6 post-injury (approximately once per week). During the sessions, the patient's current symptoms, the expected course of recovery, and the overall favourable prognosis will be discussed based on a standardized telephone script. Reassuring information and general guidance will be provided, without the intention of inducing major behavioural change.

06

What researchers measure

Primary outcomes

  1. Post-traumatic complaints (measured by Rivermead Post-concussion symptoms Questionnaire, RPQ)

    The RPQ is a validated questionnaire with sixteen questions assessing the presence and severity of post-traumatic complaints across somatic, cognitive, and emotional domains within the preceding 24 hours, in comparison to their pre-injury state. Responses are assigned on an ordinal scale from 0 to 4, with 0 indicating the absence of the complaint and 4 indicating a severe symptom.

    Time frame: Three months post-injury

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 248 non-industry interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 264 studies reached it within 28 months; a quarter within 19 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 14, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07341074
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Feb 16, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion